Comparative Pharmacology
Head-to-head clinical analysis: DOLOPHINE HYDROCHLORIDE versus KADIAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLOPHINE HYDROCHLORIDE versus KADIAN.
DOLOPHINE HYDROCHLORIDE vs KADIAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist with additional NMDA receptor antagonism and serotonin/norepinephrine reuptake inhibition. It also binds to delta and kappa opioid receptors, producing analgesic and antitussive effects.
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
Initial: 2.5-10 mg orally every 8-12 hours, titrating to effect. Maintenance: 5-20 mg orally every 8-12 hours. For severe chronic pain, dosing interval may be extended to every 12-24 hours due to long half-life. Not recommended for acute pain or as PRN analgesia.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
None Documented
None Documented
Terminal elimination half-life: 15 to 60 hours (average 24-36 hours). Clinical context: Prolonged half-life due to extensive tissue binding and redistribution; accumulates with repeated dosing, requiring careful titration to avoid toxicity.
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
Primarily renal elimination of unchanged drug (approximately 50-60%) and metabolites (including the inactive metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine). Fecal excretion accounts for about 10-20%. Biliary excretion contributes minimally (<5%) to overall elimination.
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic